Clinical monitoring for monitoring phase 2B proof of concept study for development of an HIV vaccine that meets the requirements of the US military.

Ended Awarded Last action

Contract number
0010
Awardee
Awarding agency
Obligated
$9,359,285

Award facts

Opportunity
  • W81XWH13R0038 Solicitation number
Contract value 81% obligated
  • $9,617,121.00 Current, with exercised options
  • $11,567,038.00 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
Pricing
Cost Plus Fixed Fee
Place of performance
South Africa
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action 24 · Base - monitoring of phase 2B HIV study -$257,836
Other Administrative Action 23 · Per section 711 of the 2019 ndaa, usamraa transferred to DHA 10/1/2022. $0
Other Administrative Action 22 $0
Funding Only Action 21 · Base - monitoring of phase 2B HIV study $1,025,236
Supplemental Agreement for work within scope 20 $760,025
Supplemental Agreement for work within scope 19 · This requirement is for the monitoring of phase 2B HIV study $841,420
Funding Only Action 18 · Incremental funding for monitoring of phase 2B HIV study $997,862
Funding Only Action 17 · Provide clinical monitoring of the study entitled "a multicenter, randomized, double-blind, placebo- controlled phase 2B efficacy study of a heterologous… $199,851
Funding Only Action 16 · Incremental funding in support of monitoring of phase 2B HIV study $1,200,000
Funding Only Action 15 · Incremental funding and cost adjustment for monitoring of phase 2B HIV study $253,117
Supplemental Agreement for work within scope 14 · Provide clinical monitoring of the study entitled: a multicenter, randomized, double-blind, placebo-controlled phase 2B efficacy study of a heterologous… -$353,914
Funding Only Action 13 · Modification to deobligate funding and revise incremental funding schedule. Monitoring of the phase 2B study: a multicenter, randomized, double-blind,… -$1,000,000
Funding Only Action 12 · Incremental funding for monitoring of phase 2B HIV study $294,669
Funding Only Action 11 · Provide clinical monitoring of the study entitled: a multicenter, randomized, double-blind, placebo-controlled phase 2B efficacy study of a heterologous… -$294,669
Funding Only Action 10 · The HIV vaccine program is collaborating with janssen vaccines & prevention B.V. (janssen) in development of an HIV vaccine that meets the requirements of the… $3,000,000
Funding Only Action 9 · Incremental funding in support of clinical monitoring of phase 2B HIV study. $43,051
Funding Only Action 8 · Incremental funding in the amount of $1,247,593.25 base - monitoring of phase 2B HIV study $1,247,593
Supplemental Agreement for work within scope 7 · Requirement: clinical monitoring of phase 2B HIV study this action: increase level of effort; require PPD to provide quality metrics data to janssen on a… $294,669
Funding Only Action 6 · Clinical monitoring of phase 2B HIV study $200,000
Additional Work (new agreement, FAR part 6 applies) 5 · Clinical monitoring of phase 2B HIV study. This modification adds work within scope and modifies deliverables 10 and 11. $0
Funding Only Action 4 · Clinical monitoring of phase 2B HIV study $166,337
Additional Work (new agreement, FAR part 6 applies) 3 $241,873
Additional Work (new agreement, FAR part 6 applies) 2 $0
Supplemental Agreement for work within scope 1 $300,000
Original award $200,000
Show all 25

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded a $11.6 million delivery order against its Medical Product Research and Development master IDIQ contract to PPD Development LP. This cost-plus-fixed-fee order is to provide clinical monitoring services for a Phase 2B proof of concept study being conducted in South Africa. The study aims to develop an HIV vaccine that meets the requirements of the U.S. Military. Performance will take place in South Africa over a five year period concluding in October 2022. No set aside designation or major subcontractors are indicated. The award supports the Defense Health Agency's efforts to research and develop medical solutions for members of the U.S. armed forces.

Quick answers

Who was awarded contract 0010?

0010 was awarded to PPD Development LP by Defense Health Agency (Department of Defense) on July 24, 2017.

How much is contract 0010 worth?

The government has obligated $9,359,285 on 0010. Its current value, with exercised options, is $9,617,121. Its potential value, with all options, is $11,567,038.

Is contract 0010 an order under another contract?

Yes. 0010 is a delivery order under W81XWH15D0038, an indefinite delivery contract, on Medical Product Research and Development.

Was contract 0010 competed?

The extent of competition for 0010 was full and open competition. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login